Bemarituzumab

Zai Lab reports Q3 2024 net product revenue growth of 47% y-o-y to $101.8M, positive China bridging study results for KarXT in schizophrenia, and global Phase 1 data suggesting best-in-class potential for ZL-1310 in extensive-stage SCLC. The company expects three product launches in China by end of 2024 and up to four NMPA regulatory submissions in the next six months. Cash position was $716.1M as of September 30, 2024.

NK cell therapy, a promising cancer treatment, sees robust R&D with 140+ companies developing 160+ therapies. Key players include Amgen, Innate Pharma, Nektar Therapeutics, and others. Promising therapies like Bemarituzumab, Monalizumab, and NKTR-225 are in various clinical phases. Recent milestones include Immunitybio's CAR-NK cell therapy for NHL, Nkarta's NKX019 for AAV, and KGen Biotech's SNK01 advancing to Phase II.

Amgen reports Q3 2024 financial results: total revenues up 23% to $8.5 billion, GAAP EPS increased 62% to $5.22, non-GAAP EPS up 13% to $5.58, driven by strong product sales and pipeline investments.